Teva Pharmaceutical Industries Limited (TLV:TEVA)
| Market Cap | 92.65B |
| Revenue (ttm) | 55.55B |
| Net Income (ttm) | 2.36B |
| Shares Out | n/a |
| EPS (ttm) | 2.04 |
| PE Ratio | 39.24 |
| Forward PE | 9.37 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 997,547 |
| Average Volume | 2,140,000 |
| Open | 8,139.00 |
| Previous Close | 8,177.00 |
| Day's Range | 8,077.00 - 8,296.00 |
| 52-Week Range | 4,865.00 - 8,480.00 |
| Beta | 0.70 |
| RSI | 65.34 |
| Earnings Date | Nov 5, 2025 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
Financial Performance
In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.
Financial numbers in USD Financial StatementsNews
This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He’s Buying Now.
Stanley Druckenmiller has been one of the most successful investors, a billionaire with a long record of high returns in global macro investing. He’s now piling into Natera (NASDAQ:NTRA), Insmed (NASD...
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December
TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and other members of execu...
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi's 2025 Global Healthcare Conference in December
TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and other members of execu...
Jury Convicts Done Global Founder In Adderall Distribution Scheme: WSJ Report
A federal jury has convicted Ruthia He, the founder of the telehealth startup Done Global, for orchestrating a scheme that transformed the company into an unrestricted source for Adderall prescription...
Teva (TEVA) Launches Innovative Platform to Drive Technological Advancement
Teva (TEVA) Launches Innovative Platform to Drive Technological Advancement
Teva seeks startups to help solve global pharmaceutical challenges
Teva Pharmaceutical Industries said on Wednesday it was calling on startups to join its new platform to develop technologies to deal with a host of challenges facing Teva and the global pharmaceutical...
Insider Sell: Christine Fox Sells 30,000 Shares of Teva Pharmaceutical Industries Ltd (TEVA)
Insider Sell: Christine Fox Sells 30,000 Shares of Teva Pharmaceutical Industries Ltd (TEVA)
Gleview Capital Adjusts Portfolio, Increases Stake in Teva Pharmaceutical (TEVA)
Gleview Capital Adjusts Portfolio, Increases Stake in Teva Pharmaceutical (TEVA)
Generics Stalwart Teva Has Turned A Corner In Its Specialty Medicines Business
See how Teva Pharmaceutical Industries Limited's growth strategy and focus on specialty medicines are driving a turnaround. Click for more on TEVA and its earnings.
Insider Selling: Amir Weiss Unloads $300K Of Teva Pharmaceutical Indus Stock
A substantial insider sell was reported on November 10, by Amir Weiss , Chief Accounting Officer at Teva Pharmaceutical Indus (NYSE: TEVA), based on the recent SEC filing. What Happened: A Form 4 fil...
Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today
Teva Pharmaceutical Indus (NYSE: TEVA) has outperformed the market over the past 5 years by 6.92% on an annualized basis producing an average annual return of 20.65%. Currently, Teva Pharmaceutical I...
Teva Pharmaceutical Industries Limited (TEVA) Presents at UBS Global Healthcare Conference 2025 Transcript
Price Over Earnings Overview: Teva Pharmaceutical Indus
In the current session, the stock is trading at $24.04, after a 0.29% spike. Over the past month, Teva Pharmaceutical Indus Inc. (NYSE: TEVA) stock increased by 19.72% , and in the past year, by 40.7...
Teva (TEVA) Reveals Promising Data on AUSTEDO for Tardive Dyskinesia
Teva (TEVA) Reveals Promising Data on AUSTEDO for Tardive Dyskinesia
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
PARSIPPANY, N.J., and TEL AVIV, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the prese...
Decoding Teva Pharmaceutical Industries Ltd (TEVA): A Strategic SWOT Insight
Decoding Teva Pharmaceutical Industries Ltd (TEVA): A Strategic SWOT Insight
JP Morgan Raises Teva Pharmaceutical (TEVA) Price Target to $28 | TEVA Stock News
JP Morgan Raises Teva Pharmaceutical (TEVA) Price Target to $28 | TEVA Stock News
TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up
Teva stock jumps after third-quarter earnings and revenues top estimates, driven by robust Austedo sales as well as U.S. generics growth.
Why Teva Pharmaceutical Stock Rocked the Market Today
The company delivered a convincing pair of beats in its third-quarter earnings report.
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2025 Earnings Call Highlights: Strong Growth ...
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2025 Earnings Call Highlights: Strong Growth Amidst Market Challenges
Teva Pharmaceutical (TEVA) Reports Strong Q3 2025 Growth
Teva Pharmaceutical (TEVA) Reports Strong Q3 2025 Growth
Q3 2025 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Q3 2025 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Teva outlines path to $2.5B AUSTEDO revenue in 2027 as innovative portfolio grows 33%
Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working
Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent quarter, what's driving growth, and much more.